T
20.23
0.28 (1.40%)
| Previous Close | 19.95 |
| Open | 20.05 |
| Volume | 1,841,624 |
| Avg. Volume (3M) | 1,849,895 |
| Market Cap | 1,796,521,088 |
| Price / Sales | 7.11 |
| Price / Book | 31.56 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -137.90% |
| Operating Margin (TTM) | -79.34% |
| Diluted EPS (TTM) | -4.07 |
| Quarterly Revenue Growth (YOY) | 66.00% |
| Total Debt/Equity (MRQ) | 679.76% |
| Current Ratio (MRQ) | 2.08 |
| Operating Cash Flow (TTM) | -237.48 M |
| Levered Free Cash Flow (TTM) | -228.53 M |
| Return on Assets (TTM) | -23.15% |
| Return on Equity (TTM) | -246.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Travere Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 109.23% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 47.00 (Canaccord Genuity, 132.33%) | Buy |
| 47.00 (Guggenheim, 132.33%) | Buy | |
| Median | 35.00 (73.01%) | |
| Low | 23.00 (Stifel, 13.69%) | Hold |
| Average | 36.71 (81.46%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 18.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 02 May 2025 | 23.00 (13.69%) | Hold | 20.76 |
| Wedbush | 02 May 2025 | 30.00 (48.29%) | Buy | 20.76 |
| Guggenheim | 14 Apr 2025 | 47.00 (132.33%) | Buy | 14.83 |
| Canaccord Genuity | 10 Apr 2025 | 47.00 (132.33%) | Buy | 13.49 |
| B of A Securities | 01 Apr 2025 | 31.00 (53.24%) | Buy | 17.44 |
| JP Morgan | 26 Feb 2025 | 44.00 (117.50%) | Buy | 21.03 |
| Citigroup | 24 Feb 2025 | 35.00 (73.01%) | Buy | 21.23 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |